Elucidation of new binding interactions with the human Tsg101 protein using modified HIV-1 Gag-p6 derived peptide ligands

ACS Medicinal Chemistry Letters

Volumn 2, Issue 5, 2011, Pages 337-341

  Kim, Sung Eun ^a   Liu, Fa ^a   Im, Young Jun ^b   Stephen, Andrew G ^a   Fivash, Matthew J ^a   Waheed, Abdul A ^a   Freed, Eric O ^a   Fisher, Robert J ^a   Hurley, James H ^b   Burke, Terrence R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b National Institute of Diabetes and Digestive and Kidney   (United States)

Author keywords

peptide analogues; Protein protein interactions; Tsg101; X ray crystal structure

Indexed keywords

AMIDE; AMINOOXYACETIC ACID; FUNCTIONAL GROUP; GAG PROTEIN; GLUTATHIONE TRANSFERASE; LIGAND; OXIME; P6 PROTEIN; PEPTIDE; PEPTIDES AND PROTEINS; PYRROLIDINE DERIVATIVE; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANISOTROPY; ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; HYDROGEN BOND; IC 50; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79956161071     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml1002579     Document Type: Article

References (28)

1. Drews, J. Drug discovery: A historical perspective Science 2000, 287, 1960-1964 (Pubitemid 30158662)
2. Betzi, S.; Guerlesquin, F.; Morelli, X. Protein-protein interaction inhibition (2P2I): Fewer and fewer undruggable targets Comb. Chem. High Throughput Screening 2009, 12, 968-983
3. Clackson, T.; Wells, J. A hot spot of binding energy in a hormone-receptor interface Science 1995, 267, 383-386
4. Wells, J. A.; McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces Nature 2007, 450, 1001-1009 (Pubitemid 350273630)
5. Gerrard, J. A.; Hutton, C. A.; Perugini, M. A. Inhibiting protein-protein interactions as an emerging paradigm for drug discovery Mini-Rev. Med. Chem. 2007, 7, 151-157 (Pubitemid 46592178)
6. Zinzalla, G.; Thurston, D. E. Targeting protein-protein interactions for therapeutic intervention: A challenge for the future Future Med. Chem. 2009, 1, 65-93
7. De Clercq, E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV Int. J. Antimicrob. Agents 2009, 33, 307-320
8. Hatano, H.; Lampiris, H.; Fransen, S.; Gupta, S.; Huang, W.; Hoh, R.; Martin, J. N.; Lalezari, J.; Bangsberg, D.; Petropoulos, C.; Deeks, S. G. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy J. Acquired Immune Defic. Syndr. 2010, 54, 389-393
9. Rice, A. P.; Sutton, R. E. Targeting protein-protein interactions for HIV therapeutics Future HIV Ther. 2007, 1, 369-385
10. Huang, M.; Orenstein, J.; Martin, M.; Freed, E. p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease J. Virol. 1995, 69, 6810-6818
11. VerPlank, L.; Bouamr, F.; LaGrassa, T. J.; Agresta, B.; Kikonyogo, A.; Leis, J.; Carter, C. A. Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag) Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 7724-7729 (Pubitemid 32642628)
12. Garrus, J. E.; von Schwedler, U. K.; Pornillos, O. W.; Morham, S. G.; Zavitz, K. H.; Wang, H. E.; Wettstein, D. A.; Stray, K. M.; Cote, M.; Rich, R. L.; Myszka, D. G.; Sundquist, W. I. Tsg101 and the Vacuolar protein sorting pathway are essential for HIV-1 budding Cell 2001, 107, 55-65 (Pubitemid 32972037)
13. Martin-Serrano, J.; Zang, T.; Bieniasz, P. D. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress Nat. Med. 2001, 7, 1313-1319 (Pubitemid 34007935)
14. Freed, E. O. The HIV-TSG101 interface: Recent advances in a budding field Trends Microbiol. 2003, 11, 56-59 (Pubitemid 36207497)
15. Chen, H.; Liu, X.; Li, Z.; Zhan, P.; De Clercq, E. TSG101: A novel anti-HIV-1 drug target Curr. Med. Chem. 2010, 17, 750-758
16. Demirov, D. G.; Ono, A.; Orenstein, J. M.; Freed, E. O. Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 955-960 (Pubitemid 34106617)
17. Pornillos, O. W.; Alam, S. L.; Davis, D. R.; Sundquist, W. I. Structure of the Tsg101 UEV domain in complex with the PTAP motif of the HIV-1 p6 protein Nat. Struct. Biol. 2002, 9, 812-817 (Pubitemid 35257779)
18. Liu, F.; Thomas, J.; Burke, T. R., Jr. Synthesis of a homologous series of side-chain-extended orthogonally protected aminooxy-containing amino acids Synthesis 2008, 2432-2438
19. Liu, F.; Stephen, A. G.; Fisher, R. J.; Burke, T. R., Jr. Protected aminooxyprolines for expedited library synthesis: Application to Tsg101-directed proline-oxime containing peptides Bioorg. Med. Chem. Lett. 2008, 18, 1096-1101 (Pubitemid 351179331)
20. Liu, F.; Stephen, A. G.; Waheed, A. A.; Aman, M. J.; Freed, E. O.; Fisher, R. J.; Burke, T. R., Jr. SAR by oxime-containing peptide libraries: Application to Tsg101 ligand optimization Chembiochem 2008, 9, 2000-2004
21. Im, Y. J.; Kuo, L.; Ren, X.; Burgos, P. V.; Zhao, X.-Z.; Liu, F.; Burke, T. R., Jr.; Bonifacino, J. S.; Freed, E. O.; Hurley, J. H. Crystallographic and functional analysis of the ESCRT-I /HIV-1 Gag PTAP interaction Structure (Cambridge, MA) 2010, 18, 1536-1547
22. Rigid receptor docking was performed according to standard protocols using ICM Chemist Pro Software v 3.7-1f/MacOSX; MolSoft LLC: La Jolla, CA; https://www.molsoft.com/icm-chemist-pro.html.
23. Totrov, M.; Abagyan, R. Protein-ligand docking as an energy optimization problem. In Drug-Receptor Thermodynamics: Introduction and Applications; Raffa, R. B., Ed.; John Wiley & Sons, Inc.: New York, 2001; pp 603 - 624.
24. New peptide oximes were prepared by procedures previously reported in ref 15. Experimental specifics are included in the Supporting Information.
25. Liu, F.; Stephen, A. G.; Adamson, C. S.; Gousset, K.; Aman, M. J.; Freed, E. O.; Fisher, R. J.; Burke, T. R., Jr. Hydrazone- and hydrazide-containing N-substituted glycines as peptoid surrogates for expedited library synthesis: Application to the preparation of Tsg101-directed HIV-1 budding antagonists Org. Lett. 2006, 8, 5165-5168 (Pubitemid 44728904)
26. Nguyen, J. T.; Turck, C. W.; Cohen, F. E.; Zuckermann, R. N.; Lim, W. A. Exploiting the basis of proline recoginition by SH3 and WW domains: Design of N-substituted inhibitors Science 1998, 282, 2088-2091
27. Nguyen, J. T.; Porter, M.; Amoui, M.; Miller, W. T.; Zuckermann, R. N.; Lim, W. A. Improving SH3 domain ligand selectivity using a non-natural scaffold Chem. Biol. 2000, 7, 463-473 (Pubitemid 30466981)
28. Direct fluoresence anisotropy binding assays reported in refs 20 and 25 were conducted with peptides having FITC groups appended via N-terminal 6-aminohexanoyl chains.